# US 2026/0061054 A1 · Nanoparticles for delivery of immunoregulatory materials to t cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061054 A1
- Document ID: US20260061054A1
- Status: Published application
- Kind: A1
- Application number: 19/314,956
- Filed: 2025-08-29
- Published: 2026-03-05
- Earliest claimed: 2022-10-05
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Jonathan SCHNECK; Ariel ISSER; Si-Sim KANG
- Web page: https://patentgrep.com/patent/US20260061054A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/41: Vertebrate antigens
- A61K 40/4213: {CD74, Ii, MHC class II invariant chain or MHC class II gamma chain}
- A61K 40/453: {Clostridium, e.g. Clostridium tetani}
- A61K 40/46: Viral antigens
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/2818: {against CD28 or CD152}
- C12N 5/0087: {Purging against subsets of blood cells, e.g. purging alloreactive T cells}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/75: Agonist effect on antigen
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Artificial antigen presenting cells (aAPC) including a major histocompatibility class II (MHC II) molecule and methods of their use for identifying, isolating, or detecting one or more antigen-specific T cells, and treating a disease, disorder, or condition, including cancer, are disclosed.

## Claims

### Claim at position 1

1-111. (canceled)

### Claim 112

An artificial antigen-presenting cell (αAPC) comprising:
(a) a particle having a major histocompatibility complex class II (MHC II) molecule conjugated to a surface thereof, and
(b) a T-cell costimulatory ligand conjugated to the surface;
wherein the MHC II molecule comprises an MHC II I-Ab monomer or a human leukocyte antigen (HLA) class II monomer selected from HLA-DR, HLA-DP, and HLA-DQ, the HLA class II monomer optionally being fused to an Fc domain or comprising a cysteine substitution.

### Claim 113 (depends on 112)

The αAPC of claim 112, wherein the costimulatory ligand is selected from the group consisting of CD28, CD80 (B7-1), CD86 (B7-2), B7-H3, 4-1BBL, 4-1BB, CD27, CD30, CD134 (OX-40L), B7h (B7RP-1), CD40, LIGHT, HVEM, CD40L, OX40, and 4-1BB, or an antibody or antigen-binding fragment thereof that specifically binds any of the foregoing.

### Claim 114 (depends on 112)

The adapt of claim 112, wherein the costimulatory ligand comprises an anti-CD28 antibody or antigen-binding fragment thereof.

### Claim 115 (depends on 112)

The αAPC of claim 112, wherein the MHC II molecule comprises HLA-DR1, HLA-DR4, or HLA-DP4, optionally linked to a cleavable thrombin linker enabling peptide exchange, or fused to an Fc domain comprising a cysteine at position 473.

### Claim 116 (depends on 112)

The αAPC of claim 112, further comprising a major histocompatibility complex class I molecule conjugated to the surface, wherein the class I molecule comprises an HLA-A2-Ig dimer.

### Claim 117 (depends on 112)

The αAPC of claim 112, wherein the particle comprises a paramagnetic iron-dextran nanoparticle.

### Claim 118 (depends on 112)

The αAPC of claim 112, further comprising an immunomodulatory material comprising a genetic or pharmacologic agent, or provided in a kit together with one or more antigenic peptides for loading into the MHC II molecule and written instructions for expanding antigen-specific T cells.

### Claim 119 (depends on 112)

A method for producing antigen-specific human CD4+ T cells comprising:
(a) obtaining CD4+ T cells from a human subject;
(b) contacting the CD4+ T cells in vitro with a plurality of αAPCs according to claim 112, each presenting a peptide antigen; and
(c) expanding the contacted CD4+ T cells to produce an enriched population of tetramer-positive, antigen-specific CD4+ T cells that express granzyme B and perform and exhibit antigen-specific cytotoxicity.

### Claim 120 (depends on 119)

The method of claim 119, wherein the peptide antigen is selected from tetanus toxoid p30 peptide and a Herpes Simplex Virus (HSV) peptide, and the expanded T cells secrete IFN-γ, TNF-α, IL-2, granzyme B, and perform upon antigen stimulation.

### Claim 121 (depends on 119)

The method of claim 119, wherein the antigen-specific CD4+ T cells comprise stem-cell memory (Tscm), central memory (Tcm), and effector memory (Tem) subsets.

### Claim 122 (depends on 119)

The method of claim 119, wherein the CD4+ T cells are cultured in the presence of cytokines selected from IL-2, IL-4, IL-6, IL-1p, and IFN-γ, and the expansion yields at least a 1000-fold increase in antigen-specific T cell number after 14 days.

### Claim 123 (depends on 119)

The method of claim 119, wherein the contacting step is performed for about 2 hours at about 37° C. and a ratio of about 30 ng MHC II per 106 CD4+ T cells.

### Claim 124 (depends on 119)

The method of claim 119, further comprising co-activating CD8+ T cells or redirecting CD4+ T cell help of one specificity toward CD8+ T cells of multiple specificities, wherein the contacting and separation are performed using magnetic enrichment of αAPC-bound cells.

### Claim 125

A method of treating a disease, disorder, or condition in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising antigen-specific human CD4+ T cells that:
(a) specifically recognize a peptide antigen presented by a human leukocyte antigen class II (HLA class II) molecule; and
(b) express granzyme B and perform and mediate antigen-specific cytotoxicity.

### Claim 126 (depends on 125)

The method of claim 125, wherein the disease, disorder, or condition is cancer and the antigen-specific CD4+ T cells recognize a tumor-associated antigen presented by a human leukocyte antigen class II (HLA class II) molecule.

### Claim 127 (depends on 126)

The method of claim 126, wherein the tumor-associated antigen is presented by HLA-DP4 and the CD4+ T cells are specific for a tumor-associated peptide antigen selected from melanoma, breast, colon, ovarian, lung, glioma, or multiple-myeloma antigens.

### Claim 128 (depends on 125)

The method of claim 125, wherein the disease or condition is a viral infection caused by Herpes Simplex Virus (HSV) and the CD4+ T cells specifically recognize an HLA-DP4-restricted HSV peptide.

### Claim 129 (depends on 125)

The method of claim 125,
wherein the CD4+ T cells mediate at least 90 percent antigen-specific killing of peptide-pulsed target cells in vitro and comprise a stem-cell-memory (Tscm) subset that enhances long-term persistence in vivo;
wherein the CD4+ T cells secrete IFN-γ, TNF-α, IL-2, granzyme B, and perform upon antigen stimulation and antigen-specific cytotoxicity is dependent on granzyme B activity.

### Claim 130 (depends on 125)

The method of claim 125, wherein the composition comprises tetramer-positive antigen-specific CD4+ T cells that express an NK-like cytotoxic transcriptional program characterized by expression of GZMB, PRF1, GNLY, NKG7, and FCGR3A.

### Claim 131 (depends on 125)

The method of claim 125, wherein the subject is administered checkpoint-inhibitor therapy in combination with the antigen-specific CD4+ T cells, the checkpoint inhibitor targeting PD-1, PD-L1, or CTLA-4.
